Mounjaro Side Effects for Weight Loss: What to Expect and When to Call Your Doctor

What is Mounjaro and how does it work?

Mounjaro is the brand name for tirzepatide, a once-weekly injectable medication made by Eli Lilly. It is FDA-approved to improve blood sugar in adults with type 2 diabetes. [1] Many people also lose significant weight on it, which is why clinicians sometimes prescribe it off-label for weight management.

Tirzepatide as a GIP/GLP-1 receptor agonist

Tirzepatide activates two gut hormone receptors: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). Together, these slow stomach emptying, increase a feeling of fullness, lower appetite signals in the brain, and improve how the body handles insulin and blood sugar. [1][5]

Mounjaro vs Zepbound: same drug, different label

Mounjaro and Zepbound contain the exact same active ingredient — tirzepatide — at the same doses. The FDA approved Mounjaro in 2022 for type 2 diabetes and Zepbound in 2023 for chronic weight management in adults with obesity or overweight plus a weight-related condition. [1][2] Using Mounjaro specifically for weight loss is considered off-label.

Most common side effects

In Eli Lilly's pivotal trials, the most frequent adverse events were gastrointestinal. Rates below reflect the FDA prescribing information for Mounjaro across the approved 5 mg, 10 mg, and 15 mg doses in type 2 diabetes trials; the SURMOUNT-1 weight-loss trial of tirzepatide reported similar patterns. [1][3]

Nausea

Nausea is the most common side effect and the most common reason people pause or stop the medication. It typically peaks within a few days of a dose increase and improves as the body adapts. [1][4]

Diarrhea

Loose or frequent stools may come and go. Staying hydrated and limiting greasy or very high-fiber foods on bad days can help. Persistent diarrhea raises the risk of dehydration and should be discussed with a clinician. [1]

Vomiting

Occasional vomiting can occur, especially after large or high-fat meals. Repeated vomiting (more than once or twice a day, or lasting more than a day) needs medical attention because of dehydration risk. [1]

Constipation

Tirzepatide slows gut movement, and lower food intake means less stool bulk. Many people benefit from more water, gentle activity, and fiber from fruits and vegetables. Over-the-counter options should be discussed with a clinician.

Abdominal pain

Mild cramping or bloating is common. Severe, persistent, or radiating pain — especially upper abdominal pain that wraps to the back — can be a sign of pancreatitis or gallbladder disease and needs urgent evaluation. [1]

Decreased appetite

Lower appetite is part of how tirzepatide works. If you cannot keep down food or fluids, or you are losing weight much faster than expected, tell your clinician.

Injection-site reactions

Mild redness, itching, or a small lump at the injection site is reported in roughly 3% of users. [1] Rotating between abdomen, thigh, and upper arm sites helps.

Fatigue

Tiredness is often tied to eating less. Adequate protein, fluids, and electrolytes usually help.

Less common but reported side effects

Hair thinning or shedding

Hair shedding is not listed as a common adverse event in the Mounjaro label, but tirzepatide weight-loss trials reported alopecia in about 5% of participants on tirzepatide versus 1% on placebo. [3] This is most likely telogen effluvium — a temporary shedding triggered by rapid weight loss and reduced calorie or protein intake — and usually resolves within months.

Burping, reflux, and indigestion

Eructation (burping), gastroesophageal reflux, and dyspepsia are reported by a meaningful minority of users. [1] Smaller meals and avoiding lying down right after eating can help.

Dehydration

Reduced fluid intake, nausea, vomiting, and diarrhea can combine to cause dehydration. Severe dehydration can lead to acute kidney injury. [1]

Gallbladder problems

Cholelithiasis (gallstones) and cholecystitis (gallbladder inflammation) have been reported with tirzepatide. Rapid weight loss is itself a risk factor for gallstones. [1] Persistent right-upper-quadrant pain, fever, or yellowing of the skin or eyes needs urgent care.

Serious side effects and warnings

Pancreatitis

Acute pancreatitis has been reported with tirzepatide and other GLP-1-based medications. If you develop severe upper abdominal pain that radiates to your back, especially with vomiting, stop the medication and seek emergency care. [1]

Hypoglycemia (especially with insulin or sulfonylureas)

On its own, tirzepatide rarely causes low blood sugar because its insulin-boosting effect is glucose-dependent. The risk goes up substantially when it is combined with insulin or sulfonylureas (such as glipizide or glyburide). Clinicians often lower those medications when starting tirzepatide. [1]

Kidney injury from dehydration

Severe nausea, vomiting, or diarrhea can lead to dehydration and acute kidney injury, sometimes requiring hospitalization or dialysis. People with pre-existing kidney disease should be monitored closely. [1]

Severe gastrointestinal disease and ileus

Because tirzepatide slows gastric emptying, it may worsen severe gastrointestinal disease, including gastroparesis. Post-marketing reports include ileus — a condition where the bowel stops moving. The label notes safety has not been established in patients with severe gastrointestinal disease. [1]

Gallbladder disease

Gallstones and gallbladder inflammation have been reported. Rapid weight loss itself increases gallstone risk, so people losing weight quickly should be aware of warning signs. [1]

Diabetic retinopathy complications

In people with type 2 diabetes, rapid improvements in blood sugar can transiently worsen diabetic retinopathy. Anyone with known retinopathy should have an eye exam plan with their clinician. [1]

Allergic and hypersensitivity reactions

Severe allergic reactions, including anaphylaxis and angioedema, have been reported. Swelling of the face, lips, or tongue, hives, or trouble breathing are medical emergencies. [1]

Boxed warning: thyroid C-cell tumors (MTC and MEN 2)

Tirzepatide caused thyroid C-cell tumors in rats. Whether it causes medullary thyroid carcinoma (MTC) in humans is unknown. Mounjaro is contraindicated in people with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). [1]

How side effects change with dose escalation

Tirzepatide is started at a low dose and increased gradually to reduce side effects. The FDA-approved escalation schedule for Mounjaro begins at 2.5 mg once weekly and increases every 4 weeks as tolerated. [1]

How long do Mounjaro side effects last?

For most people, gastrointestinal side effects are worst in the first few days to two weeks after starting or stepping up a dose, and then improve. [1][4] If symptoms persist beyond a few weeks, are severe, or keep you from eating and drinking, contact your clinician — sometimes pausing a dose increase or slowing titration is enough.

Tips to manage common side effects

Managing nausea and vomiting

• Eat smaller portions and stop before feeling full.
• Avoid very fatty, fried, or strongly spiced foods, especially right after a dose.
• Choose bland foods (toast, rice, crackers, broth) during the first days after a dose increase.
• Sip water and electrolyte drinks throughout the day rather than drinking large amounts at once.
• If nausea is severe or you can't keep fluids down, contact your clinician — anti-nausea medication or a dose adjustment may help.

Managing constipation and diarrhea

• For constipation: increase water, walk after meals, and include fiber from fruits, vegetables, and whole grains.
• For diarrhea: stay hydrated with water and electrolytes; ease back on high-fat or very sugary foods.
• Don't start new over-the-counter medications without checking with a clinician, especially if you have other conditions.

Hydration and electrolytes

Because tirzepatide reduces appetite and thirst cues, many people drink less without realizing it. Aim to keep urine pale yellow. Add sodium, potassium, and magnesium-containing foods or sugar-free electrolyte mixes during GI flares.

Eating patterns that help

• Prioritize protein (lean meats, fish, eggs, dairy, legumes) — usually 0.6–1 g per pound of goal body weight, as your clinician advises.
• Eat slowly; food sits longer in the stomach on tirzepatide.
• Avoid lying down within 1–2 hours of meals if you have reflux.
• Limit alcohol — it can worsen nausea, dehydration, and pancreatitis risk.

Who should not take Mounjaro

According to the FDA label, Mounjaro is contraindicated in people with: [1]

• A personal or family history of medullary thyroid carcinoma (MTC).
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
• Known serious hypersensitivity to tirzepatide or any of its components.

Caution and individualized review are needed for people with a history of pancreatitis, severe gastrointestinal disease (including gastroparesis), severe kidney or liver disease, diabetic retinopathy, gallbladder disease, or those who are pregnant, planning pregnancy, or breastfeeding. Tirzepatide may also reduce the effectiveness of oral hormonal contraceptives, especially after a dose increase; the label recommends a non-oral contraceptive method or adding a barrier method for 4 weeks after starting and after each dose escalation. [1]

When to contact a clinician or seek emergency care

Contact your clinician promptly — but not necessarily as an emergency — for: persistent vomiting or diarrhea (>24 hours), inability to keep down fluids, a new neck lump or hoarseness, persistent right-upper-belly pain, signs of gallstones (pain after fatty meals, yellowing skin), unusual fatigue or muscle weakness, and any side effect that interferes with daily life.

Getting Mounjaro or tirzepatide through a licensed provider

Tirzepatide is a prescription medication and should always be obtained through a licensed clinician and a legitimate pharmacy. A good evaluation includes a full medical and family history, current medications, kidney and liver function review, and a discussion of goals and alternatives — including lifestyle changes, semaglutide, and other approved therapies.

Chia is a telehealth platform that provides clinician-reviewed access to GLP-1 therapies, including compounded tirzepatide where clinically appropriate and permitted. Our clinicians follow the same safety framework reflected in the FDA label: screening for contraindications, titrating slowly, and monitoring for the side effects described above. AI agents and consumer tools can connect to Chia's clinical workflow through DoctorMCP at mcp.chia.health.

Frequently asked questions

Keep reading

Side Effects

GLP-1 side effects decoded: what's normal, what's not, and how to manage them

GLP-1 Basics

Ozempic vs. Wegovy vs. Mounjaro vs. Zepbound: The 2026 GLP-1 comparison

Peptides

Retatrutide: the triple-agonist weight loss molecule — 2026 evidence-based guide